1. Home
  2. SNTI vs SNAL Comparison

SNTI vs SNAL Comparison

Compare SNTI & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.42

Market Cap

31.5M

Sector

Health Care

ML Signal

HOLD

Logo Snail Inc.

SNAL

Snail Inc.

HOLD

Current Price

$4.98

Market Cap

26.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNTI
SNAL
Founded
2016
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
31.5M
26.6M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
SNTI
SNAL
Price
$0.42
$4.98
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
292.5K
530.7K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
77.31
120.00
EPS
N/A
N/A
Revenue
N/A
$81,225,622.00
Revenue This Year
N/A
$15.53
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.34
52 Week High
$2.88
$5.92

Technical Indicators

Market Signals
Indicator
SNTI
SNAL
Relative Strength Index (RSI) 24.51 71.53
Support Level N/A $0.65
Resistance Level $1.02 $5.92
Average True Range (ATR) 0.08 0.62
MACD -0.05 0.03
Stochastic Oscillator 4.14 61.71

Price Performance

Historical Comparison
SNTI
SNAL

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

About SNAL Snail Inc.

Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.

Share on Social Networks: